WT1 and plasma cell myeloma: As evidence of anti-tumor activity, particularly against hematological malignancies, we demonstrated that after treatment with WT1-expressing aAVC (aAVC-WT1), J558-WT1 myeloma cell-bearing mice survived for more than 6 months, and the establishment of relevant myeloma cells but not irrelevant WT1-defected tumors was blocked when rechallenged with the same tumor.